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Bladder cancer is the ninth most common malignancy worldwide [1]. It is a diverse disease with differing
outcomes related to its underlying basic biology, responsiveness to therapy, and host-related factors. As a
result, the spectrum of disease ranges from a relatively benign entity that is more bothersome than anything
to a lethal variant with great metastatic potential. For these reasons, early detection, markers of disease
outcome, and good surgical and medical therapies are paramount to impacting its natural history. Over the
last 30 years, advances in endoscopic and surgical technique together with discoveries with immuno- and
chemotherapy have resulted in substantial improvements to the care of patients suffering from this disease.
With emerging techniques in outcomes research and with better access to tissue banks, better markers for
disease outcome hold great promise to reconcile some of the heterogeneity seen. In this series of papers, we
have highlighted recent discoveries that establish a new and emerging standard of care for the management
of bladder cancer patients. These papers also demonstrate shortcomings of our current care thus reminding
us, the scientiﬁc community, that we can never be complacent. We can and should do better!
The use of high-resolution and multiwavelength endoscopic cameras has resulted in the best ever
image quality. Despite this, it can be challenging to distinguish areas of inﬂammation from carcinoma in
situ and to ensure complete resection at the time of transurethral resection of bladder tumor. Among the
selected papers, P. Patel et al. reviewed the use of photodynamic techniques to further enhance cancer
detection rates. These may allow for a superior diagnostic assessment via cystoscopy and complete tumor
resection/eradication. However, these improved technologies come at a ﬁnancial cost as well as raise
questions pertaining to whether this truly alters the natural history and metastatic potential imparted by
such typically low-volume and/or grade occult bladder tumors.
Due mainly to surveillance and the escalating costs of healthcare, bladder cancer is one of the most
expensive malignancies to diagnose and treat [2, 3]. Urine-based markers may mitigate some of these
costs in the future by allowing for infrequent (if any) endoscopic evaluation and may, like photodynamic
technologies, allow for the discovery of tumors missed by conventional cystoscopy. J. Parker and P. E.
Spiess cover the topic of bladder tumor markers in a thorough review.
Once discovered by endoscopy, the aforementioned varied natural history of these tumors can lead
to treatment dilemmas especially for patients with high-grade, nonmuscle-invasive bladder cancers. These
tumors have high recurrence and progression rates and carry the risk of being understaged with potential
fatal consequences [4]. Highlighting the challenge of managing patients with high-grade nonmuscle-
invasive bladder cancer, the role for repeat resection and the recognition of BCG failure were reviewed
by the preeminent experts in the ﬁeld Drs. H. W. Herr and M. A. O’Donnell, respectively.
After the recognition of muscle invasion or the acceptance that the risk of nonmuscle-invasive
disease is intolerable, radical cystectomy must be considered. This life saving treatment has been marred
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with substantial morbidity and mortality, which have not been improved in decades [5]. Robotic-assisted,
laparoscopic approaches may represent a signiﬁcant advance as compared to the open approach. Richards
and colleagues review the early experience with this new technique holding great promise to decrease the
burden of this effective treatment.
Finally, when patients present with locally advanced or metastatic disease, neoadjuvant/adjuvant or
salvage chemotherapy should be considered. Urologists counseling their patients often poorly understand
the subtleties of the risks and beneﬁts of this toxic, systemic approach as well as the agents available in the
armamentarium. The paper by Drs. C. Constantini and F. Millard sheds some light on the subject providing
a practical, clinician-focused approach to the management of patients with aggressive disease.
With up to 50% of patients presenting for radical cystectomy dying of bladder cancer at 5 years,
clearly we have signiﬁcant room for improvement in terms of prevention, early detection, and treatment of
our patients [6]. We have chosen to focus our discussions on two areas of future research, which may help
reduce this alarming rate of cancer-speciﬁc mortality.
Some of the greatest challenge that urologists and their patients face is to reconcile the heterogeneity
of this disease and how aggressively patients should be managed in a stage-speciﬁc and/or risk-stratiﬁed
fashion. One area of research that has the potential to bear fruit is biomarkers, a topic elegantly reviewed by
Drs. R. F. Youssef and Y. Lotan.
Another area of discovery that has the potential to further our understanding of the biology of bladder
cancer and provide for future therapeutic targets is research into bladder and bladder cancer stem cells as
reviewed by Dr. R. T. Bryan.
I would like to thank the authors for their tremendous work in reviewing the body of literature that
theyhavehelpedtocontributeto.Itisthankstothemandresearcherslikethemthatwehavesuchahighlevel
of care for this debilitating and possibly lethal disease. Despite this, much work lies ahead for researchers
striving to make meaningful contributions to our ﬁeld as it pertains to this complex disease and its heavily
burdened patient population.
A. Karim Kader
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